Stockreport

According to THE SAGE GROUP, There is a Significant Need for Innovative Endovascular Devices to Treat Below-the-Ankle (BTA) Disease in Critical Limb Ischemia (CLI) Patients [Yahoo! Finance...

SAGE GROUP UNSP/ADR  (SGPYY) 
NASDAQ:AMEX Investor Relations: sage.com/corporate/investors
PDF consequences of BTA disease, as well as explores the challenges of endovascular revascularization. BTA disease is characterized by atherosclerotic stenoses and/or occl [Read more]